Feb 14, 2019 - AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.
Feb 08, 2019 - Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.
Feb 04, 2019 - Astrazeneca (AZN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Jan 18, 2019 - Pfizer's (PFE) tafamidis application gets FDA's priority review. Regulatory updates for Roche's (RHHBY) and Bristol-Myers'(BMY) cancer combination drugs in focus.
Jan 18, 2019 - Immunomedics (IMMU) receives a CRL from the FDA pertaining to the BLA for its lead breast cancer candidate, sacituzumab govitecan.
Jan 17, 2019 - NVS vs. AZN: Which Stock Is the Better Value Option?
Jan 16, 2019 - Ironwood Pharmaceuticals (IRWD) gets approval for Linzess in China for the treatment of adults with IBS-C
Jan 14, 2019 - Merck (MRK) looks well poised for 2019, carrying forward the momentum achieved last year.
Jan 07, 2019 - Ironwood Pharma (IRWD) appoints AstraZeneca executive, Mark Mellon, as its new chief executive officer. Peter Hecht, the current CEO, will lead the new spinoff company focusing on rare disease.
Jan 04, 2019 - Bristol-Myers (BMY) is spending $74 billion to buy Celgene. Merck (MRK) exercises option to gain rights to a NASH candidate from partner NGM Biopharmaceuticals.